Ujfej1olrcxdgm3oplby screen shot 2016 10 18 at 1.17.41 pm

In Silico Biosciences, Inc.

Lexington, Massachusetts, US

Despite tremendous progress in basic science, there have been few breakthroughs in the treatment of many CNS diseases. CNS quantitative systems pharmacology is based on the realization that human pathology is driven by a network imbalance rather than deficits at a single target or gene.

Computer-based modeling of biophysically realistic neuronal network circuits calibrated with human imaging and clinical data is a translational tool to assess the outcome of therapeutic interventions in complex brain circuits. The company provides insights into the systemic behavior at each R&D stage in high impact decision processes.

We provide model based decision support and knowledge support from target validation to personalized medicine for:

  • Schizophrenia (PANSS Total, PANSS Negative, Cognitive Impairment)
  • Antipsychotic-induced side effects (Extra-pyramidal symptoms, Akathisia, Prolactin increase)
    -... Show more »

Despite tremendous progress in basic science, there have been few breakthroughs in the treatment of many CNS diseases. CNS quantitative systems pharmacology is based on the realization that human pathology is driven by a network imbalance rather than deficits at a single target or gene.

Computer-based modeling of biophysically realistic neuronal network circuits calibrated with human imaging and clinical data is a translational tool to assess the outcome of therapeutic interventions in complex brain circuits. The company provides insights into the systemic behavior at each R&D stage in high impact decision processes.

We provide model based decision support and knowledge support from target validation to personalized medicine for:

  • Schizophrenia (PANSS Total, PANSS Negative, Cognitive Impairment)
  • Antipsychotic-induced side effects (Extra-pyramidal symptoms, Akathisia, Prolactin increase)
  • Alzheimer's disease (Cognition, Neuropsychiatric symptoms and Beta-amyloid dynamics)
  • Parkinson's disease (Rigidity-bradykinesia, Tremor, L-DOPA induced dyskinesia)

Our modeling addresses the following key questions:

  • Target validation
  • Clinical candidate selection
  • Support rationally designed multipharmacology drug discovery projects
  • Rational support for combination therapy
  • Clinical biomarker selection for functional target engagement
  • Dosing guidance
  • Clinical study design especially with comedications and genotypes
  • Competitive analysis
  • Clinical responder analysis
« Show less

In Silico Biosciences, Inc. has not listed any services.

Computational Modeling
Price on request

We offer computer simulation support in drug development, based on the affinity and pharmacology of a new drug towards human receptors for Alzheimer's disease, schizophrenia and Parkinson's disease.

Preclinical Discovery
Validating the impact of targets in the combined neuronal circuit outcome
Candidate selection... Show more »

We offer computer simulation support in drug development, based on the affinity and pharmacology of a new drug towards human receptors for Alzheimer's disease, schizophrenia and Parkinson's disease.

Preclinical Discovery
Validating the impact of targets in the combined neuronal circuit outcome
Candidate selection in multi-target medicinal chemistry campaign
Off-target pharmacological activity of candidate compounds
Early assessment of human metabolite effects of candidate compounds
Synergistic effects of off-target pharmacological activity of candidate compounds

Early Clinical Development
Prediction of functional biomarkers (pharmaco-fMRI, pharmaco-EEG)
Optimal dosage and dosage schedule

Late Clinical Development
Simulations of comedication effects on primary pharmacology
Effect of genotype randomization
Virtual patient trial based on pharmacokinetic and mechanistic pharmacodynamic simulation
Chronopharmacology, i.e. optimal dosing time given the circadian rhythm of specific brain circuits

Post-Marketing
Simulation of different switching schedules
Understanding the biology behind pharmacogenomics analysis of responders
Optimization of clinical head-to-head trials
Simulations of the drug in real-life conditions (i.e. polypharmacy)

« Show less

In Silico Biosciences, Inc. has not received any ratings.

Be the first to endorse In Silico Biosciences, Inc.

Endorse this lab